Tim Illidge
Impact in
- Pathology and Forensic Medicine top 0.05%
- Lymphoma Diagnosis and Treatment
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Viral-associated cancers and disorders
Papers in
-
- Lymphoma Diagnosis and Treatment 132
- Oncology 115
- CAR-T cell therapy research 36
- Cancer Immunotherapy and Biomarkers 33
- Co-authors
- Jamie Honeychurch (40 shared papers)Simon J. Dovedi (15 shared papers)Eleanor J. Cheadle (16 shared papers)Mark Steven Cragg (21 shared papers)Lena Specht (13 shared papers)Joachim Yahalom (12 shared papers)Robert W. Wilkinson (6 shared papers)Richard T. Hoppe (5 shared papers)
- Journals
- Blood (44 papers)Clinical Oncology (21 papers)British Journal of Haematology (18 papers)International Journal of Radiation Oncology*Biology*Physics (14 papers)Journal of Clinical Oncology (11 papers)
- Partner nations
- United KingdomUnited StatesFrance
In The Last Decade
Tim Illidge
241 papers receiving 15.7k citations
Tim Illidge's Hit Papers
Peers
Comparison fields: 5 of 135
- Pathology and Forensic Medicine 6.1k
- Oncology 6.5k
- Immunology 3.5k
- Dermatology 1.5k
- Genetics 1.7k
Countries citing papers authored by Tim Illidge
This map shows the geographic impact of Tim Illidge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Illidge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Illidge more than expected).
Fields of papers citing papers by Tim Illidge
This network shows the impact of papers produced by Tim Illidge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Illidge. The network helps show where Tim Illidge may publish in the future.
Co-authors
The 25 scholars most cited alongside Tim Illidge, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 249 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade Hit paper breakdown → | 2014 | 1072 |
| 2 | Consensus guidelines for the definition, detection and interpretation of immunogenic cell death Hit paper breakdown → | 2020 | 897 |
| 3 | Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study Hit paper breakdown → | 2012 | 820 |
| 4 | Consensus guidelines for the detection of immunogenic cell death Hit paper breakdown → | 2014 | 719 |
| 5 | Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial Hit paper breakdown → | 2018 | 554 |
| 6 | Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma Hit paper breakdown → | 2015 | 536 |
| 7 | Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial Hit paper breakdown → | 2003 | 500 |
| 8 | The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant Hit paper breakdown → | 2015 | 497 |
| 9 | Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial Hit paper breakdown → | 2017 | 450 |
| 10 | Modern Radiation Therapy for Hodgkin Lymphoma: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group (ILROG) Hit paper breakdown → | 2013 | 437 |
| 11 | Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2014 | 371 |
| 12 | 2017 | 309 | |
| 13 | 2015 | 292 | |
| 14 | 2018 | 291 | |
| 15 | 2011 | 288 | |
| 16 | Clinical development of new drug–radiotherapy combinations Hit paper breakdown → | 2016 | 284 |
| 17 | 2011 | 245 | |
| 18 | 2014 | 234 | |
| 19 | Immunomodulation by radiotherapy in tumour control and normal tissue toxicity Hit paper breakdown → | 2021 | 199 |
| 20 | 2017 | 190 |
About Tim Illidge
Tim Illidge is a scholar working on Pathology and Forensic Medicine, Oncology, Radiology, Nuclear Medicine and Imaging, Immunology and Dermatology, having authored 249 papers that have together received 16.1k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (132 papers), CAR-T cell therapy research (36 papers), Monoclonal and Polyclonal Antibodies Research (34 papers), Cancer Immunotherapy and Biomarkers (33 papers), Immunotherapy and Immune Responses (30 papers), Lung Cancer Treatments and Mutations (26 papers), Cutaneous lymphoproliferative disorders research (25 papers) and CNS Lymphoma Diagnosis and Treatment (24 papers). The work is most often cited by research in Pathology and Forensic Medicine (6.1k citations), Oncology (6.5k citations), Immunology (3.5k citations), Dermatology (1.5k citations) and Genetics (1.7k citations). Tim Illidge has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Jamie Honeychurch, Simon J. Dovedi, Eleanor J. Cheadle, Mark Steven Cragg, Lena Specht, Joachim Yahalom, Robert W. Wilkinson, Richard T. Hoppe, Jekaterina A. Erenpreisa and Ian James Stratford. Their work appears in journals such as Blood, Clinical Oncology, British Journal of Haematology, International Journal of Radiation Oncology*Biology*Physics and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.